Corticosteroids, but not TNF Antagonists, Associate With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases

726 1 month ago 0

Increasing age, comorbidities, and use of corticosteroids and other anti-inflammatory agents correlated with severe COVID-19 in patients with inflammatory bowel diseases (IBD), whereas treatment with tumor necrosis factor (TNF) antagonists did not, researchers report in Gastroenterology. Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents (TNF antagonists such as infliximab) are commonly

Read more
  • AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

981 3 months ago 0

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA). The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but

Read more

REVIEW: Transitioning Adolescents With Inflammatory Bowel Diseases to Adult Care

1103 5 months ago 0

Adolescents and young adults diagnosed with inflammatory bowel diseases (IBDs) in pediatric care are vulnerable during their transition to adult care. A review article in the February issue of Clinical Gastroenterology and Hepatology discusses the transition from pediatric to adult care for IBD, makes recommendations to improve this process, and identifies

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

2534 1 year ago 0

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more
  • Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

4103 2 years ago 0

In an analysis of intestinal tissues from patients with Crohn’s disease (CD), researchers identified specific changes in gene expression patterns that associate with histologic changes, such as differences in microvilli length. Decreased microvilli length, via decreased expression of the microvilli gene set, might contribute to epithelial malfunction and the chronic

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

3217 2 years ago 0

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

4209 2 years ago 0

 One-third of children with Crohn’s disease have healing in only the mucosa or the bowel wall (not both), researchers report in the July issue of Clinical Gastroenterology and Hepatology. Levels of fecal calprotectin below 300 μg/identify children with mucosal healing. In patients with CD, mucosal healing is associated with reduced risk of relapse,

Read more
  • What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

7595 2 years ago 1

When patients with Crohn’s disease in sustained remission stopped taking infliximab for a median 7 years, almost one fifth did not require retreatment or have a major complication, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Fewer than one fifth of patients required surgery or developed a complex perianal fistula. Increasing numbers of patients

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

3969 3 years ago 0

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more
  • Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

6958 3 years ago 1

Detection of flat low-grade dysplasia (fLGD) and aneuploidy in colon tissues increases risk for high-grade dysplaisa (HGD) or colorectal cancer (CRC) more than 5-fold in patients with inflammatory bowel disease (IBD), researchers report in the December issue of Gastroenterology. Aneuploidy was also detected in almost all cases of flat HGD (fHGD) IBD is a risk

Read more